Wait, we have a special offer for you! ✋

Get your exclusive discount now

YES, get the discount! No, I'd pay the full price
Global Anti Cancer MAbS Market Report 2024

Anti-Cancer MAbS Global Market Report 2024 – By Type (Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, Other Types), By Application (Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, Other Applications), By End User (Hospitals, Research Institutes, Other End Users ) – Market Size, Trends, And Global Forecast 2024-2033

Anti-Cancer MAbS Global Market Report 2024

Starting Price : $5000.00 | Pages : | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request Sample
Request For Discount
Customise Your Report
Request For Proposal
Request For Regional Data
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Anti-Cancer MAbS Global Market Report 2024

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Anti-Cancer mAbs Market Definition And Segments

Anticancer monoclonal antibodies (mAbs) are the antibodies used for monoclonal antibody therapy to target and destroy cancer cells. These mAbs are intended to bind to specific proteins or chemicals located on the surface of cancer cells, preventing cancer growth, and spread.

The main types of anti-cancer mAbs are murine antibodies, chimeric antibodies, humanized antibodies, and others. Murine refers to a type of monoclonal antibody (mAb) that is a laboratory-made copy of a single antibody, produced by a single B cell, derived from mice or rats, they are used to bind to a specific antigen. These are used in various applications such as blood cancer, breast cancer, lung cancer, melanoma, colorectal cancer, liver cancer and others and are used in hospitals, research institutes, and others.

The anti-cancer mAbs market covered in this report is segmented –

1) By Type: Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, Other Types

2) By Application: Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, Other Applications

3) By End User: Hospitals, Research Institutes, Other End Users

The anti-cancer mAbs market size has grown rapidly in recent years. It will grow from $59.98 billion in 2023 to $66.1 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to increasing cancer incidence rates, growing understanding of cancer biology, rise in personalized medicine approaches, increased investment in research and development, growing patient awareness and demand.

The anti-cancer mAbs market size is expected to see strong growth in the next few years. It will grow to $95.99 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to advancements in immunotherapy, increasing adoption of combination therapies, emergence of next-generation mAbs, global efforts to address cancer burden, expansion of patient access programs. Major trends in the forecast period include innovations in drug delivery technologies, integration of artificial intelligence in drug discovery, collaborations and partnerships in the pharma industry, advancements in biotechnology, car-t cell therapies.

Rising Global Cancer Prevalence Fuels Anticancer Monoclonal Antibodies (MABS) Market Growth

The increasing prevalence of cancer across the globe is expected to propel the growth of the anticancer MABs market going forward. Cancer refers to the disease that is a chronic disease that lasts for a longer time. Anticancer monoclonal antibodies (mAbs) are specifically designed to bind specific proteins found on cancerous cells as well as they use genetically engineered versions of the immune system's own antibodies to target and destroy cancer cells, as a result, increasing the prevalence of cancer increases the demand for anticancer MABs market. For instance, in January 2022, according to PubMed, a US-based biomedical and life sciences journal, it is estimated that around 1.9 million new cancer cases are expected to be diagnosed globally, with 609,360 cancer deaths in the United States. Therefore, increasing the prevalence of cancer across the globe is propelling the growth of the anticancer mAbs market.

The Impact Of Increasing Clinical Trials On The Anticancer Monoclonal Antibodies (MABS) Market

The growing number of clinical trials is expected to propel the growth of the anti-cancer mAbs market going forward. A clinical trial is a research study that prospectively assigns people to one or more health-related interventions to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes. Clinical trials have played a crucial role in developing and refining anti-cancer monoclonal antibodies (mAbs) as a promising therapeutic approach to provide valuable insights into the safety, efficacy, and potential mechanisms of action of various mAbs. For instance, in February 2023, according to the World Health Organization, a Switzerland-based public health agency, the global number of clinical trials increased by 20% from 616,765 trials in 2020 to 744,100 clinical trials in 2022. Therefore, the growing demand for physical therapists is driving the growth of the anti-cancer mAbs market.

Major companies operating in the anti-cancer mAbs market report are Amgen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson & Johnson, Novartis AG, Merck & Co. Inc., Spectrum Pharmaceuticals Inc., AstraZeneca plc., Pfizer Inc., Gilead Sciences Inc., Bayer HealthCare, ImmunoGen Inc., Genentech Inc., AbbVie Inc., Takeda Pharmaceuticals, Seattle Genetics, Regeneron Pharmaceuticals, Celgene, Ipsen, Daiichi Sankyo, Kite Pharma, ADC Therapeutics, MacroGenics Inc., BioXcel Therapeutics, Zymeworks Inc., Exelixis Inc., Blueprint Medicines, Erytech Pharma, Oncopeptides AB .

Product Innovations Drive Advancements In Anticancer Monoclonal Antibodies (MABS)

Product innovations are a key trend gaining popularity in the anticancer mAbs market. Major companies operating in the anticancer mAbs market are introducing more effective and targeted cancer treatments, such as mAbs drugs to strengthen their position in the market. For instance, in May 2022, Roche Holding AG, a Switzerland-based pharmaceutical company launched PHESGO. PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a unique monoclonal antibody (mAb) combination treatment for HER2-positive early breast cancer. It is a subcutaneous (under the skin) injection that combines the two mAbs pertuzumab and trastuzumab with the enzyme hyaluronidase. The addition of hyaluronidase, an enzyme that helps to increase the absorption of the mAbs, allows the treatment to be given subcutaneously rather than intravenously.

Innovative Approaches In Anticancer Monoclonal Antibodies Market

Major companies operating in the anti-cancer mAbs market are focused on developing innovative solutions, such as clinical trials, to gain a competitive edge in the market. Clinical trials are research studies that evaluate new treatments, medications, or devices in human participants, helping to determine whether new interventions are safe and effective. For instance, in April 2023, Y-mAbs Therapeutics Inc., a US-based clinical biopharmaceutical company, launched the Phase I Trial of GD2-Targeted Radioimmunotherapy. The Phase 1 trial evaluates the safety and efficacy of GD2-SADA, pre-targeted radioimmunotherapy (RIT) for treating certain GD2-positive solid tumors, including small cell lung cancer, sarcoma, and malignant melanoma. GD2-SADA is a novel RIT that uses a two-step approach to deliver radiation to tumor cells. First, the SADA protein is administered, which binds to GD2, a protein found on the surface of many solid tumors. Next, the radioactive ligand 177Lu-DOTA is administered, which binds to the SADA protein and delivers radiation to the tumor cells. This two-step approach is designed to minimize radiation exposure to healthy tissues.

Exelixis Expands Drug Portfolio With Acquisition Of GamaMabs Pharma

In May 2021, Exelixis Inc., a US-based genomics-based drug discovery company acquired GamaMabs Pharma SA for an amount of $5 million. With the acquisition of GamaMabs’ AMHR2 antibody technology, Exelixis Inc. aims to add an existing drug product portfolio of GamaMabs and related manufacturing cell lines. GamaMabs Pharma SA is a France-based biotechnology focused on developing innovative monoclonal antibodies for the treatment of solid tumors.

North America was the largest region in the anti-cancer MAbS market in 2023. Asia Pacific is expected to be the fastest-growing region in the anti-cancer MAbS market during the forecast period. The regions covered in the anti-cancer mAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the anti-cancer mAbs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anticancer mAbs market consists of sales of monoclonal antibody therapies such as avastin, Herceptin, keytruda, opdivo, darzalex, and perjeta. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The anti-cancer MABs market research report is one of a series of new reports from The Business Research Company that provides anti-cancer MABs market statistics, including anti-cancer MABs industry global market size, regional shares, competitors with an anti-cancer MABs market share, detailed anti-cancer MABs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-cancer MABs industry. This anti-cancer MABs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anti-Cancer MAbS Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $66.1 billion
Revenue Forecast In 2033 $95.99 billion
Growth Rate CAGR of 9.8% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Type: Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, Other Types
2) By Application: Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, Other Applications
3) By End User: Hospitals, Research Institutes, Other End Users
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled Amgen Inc.; Bristol Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc; Johnson & Johnson; Novartis AG; Merck & Co. Inc.; Spectrum Pharmaceuticals Inc.; AstraZeneca plc.; Pfizer Inc.; Gilead Sciences Inc.; Bayer HealthCare; ImmunoGen Inc.; Genentech Inc.; AbbVie Inc.; Takeda Pharmaceuticals; Seattle Genetics; Regeneron Pharmaceuticals; Celgene; Ipsen; Daiichi Sankyo; Kite Pharma; ADC Therapeutics; MacroGenics Inc.; BioXcel Therapeutics; Zymeworks Inc.; Exelixis Inc.; Blueprint Medicines; Erytech Pharma; Oncopeptides AB
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Anti-Cancer MAbS Market Characteristics

    3. Anti-Cancer MAbS Market Trends And Strategies

    4. Anti-Cancer MAbS Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On the Market

    4.2. Ukraine-Russia War Impact On the Market

    4.3. COVID-19 Impact On the Market

    5. Global Anti-Cancer MAbS Market Size and Growth

    5.1. Global Anti-Cancer MAbS Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Anti-Cancer MAbS Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Anti-Cancer MAbS Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Anti-Cancer MAbS Market Segmentation

    6.1. Global Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Murine Antibodies

    Chimeric Antibodies

    Humanized Antibodies

    Other Types

    6.2. Global Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Blood Cancer

    Breast Cancer

    Lung Cancer

    Melanoma

    Colorectal Cancer

    Liver Cancer

    Other Applications

    6.3. Global Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospitals

    Research Institutes

    Other End Users

    7. Anti-Cancer MAbS Market Regional And Country Analysis

    7.1. Global Anti-Cancer MAbS Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Anti-Cancer MAbS Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Anti-Cancer MAbS Market  

    8.1. Asia-Pacific Anti-Cancer MAbS Market Overview  

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Anti-Cancer MAbS Market  

    9.1. China Anti-Cancer MAbS Market Overview  

    9.2. China Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Anti-Cancer MAbS Market  

    10.1. India Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Anti-Cancer MAbS Market  

    11.1. Japan Anti-Cancer MAbS Market Overview  

    11.2. Japan Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Anti-Cancer MAbS Market  

    12.1. Australia Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Anti-Cancer MAbS Market  

    13.1. Indonesia Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Anti-Cancer MAbS Market  

    14.1. South Korea Anti-Cancer MAbS Market Overview  

    14.2. South Korea Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Anti-Cancer MAbS Market  

    15.1. Western Europe Anti-Cancer MAbS Market Overview

    15.2. Western Europe Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Anti-Cancer MAbS Market  

    16.1. UK Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Anti-Cancer MAbS Market  

    17.1. Germany Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Anti-Cancer MAbS Market  

    18.5. France Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.6. France Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.7. France Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Anti-Cancer MAbS Market  

    19.9. Italy Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.10. Italy Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.11. Italy Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Anti-Cancer MAbS Market  

    20.13. Spain Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.14. Spain Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.15. Spain Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Anti-Cancer MAbS Market  

    21.1. Eastern Europe Anti-Cancer MAbS Market Overview

    21.2. Eastern Europe Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Anti-Cancer MAbS Market  

    22.1. Russia Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Anti-Cancer MAbS Market  

    23.1. North America Anti-Cancer MAbS Market Overview

    23.2. North America Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Anti-Cancer MAbS Market  

    24.1. USA Anti-Cancer MAbS Market Overview

    24.2. USA Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Anti-Cancer MAbS Market  

    25.1. Canada Anti-Cancer MAbS Market Overview

    25.2. Canada Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Anti-Cancer MAbS Market  

    26.1. South America Anti-Cancer MAbS Market Overview

    26.2. South America Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Anti-Cancer MAbS Market  

    27.1. Brazil Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Anti-Cancer MAbS Market  

    28.1. Middle East Anti-Cancer MAbS Market Overview

    28.2. Middle East Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Anti-Cancer MAbS Market  

    29.1. Africa Anti-Cancer MAbS Market Overview

    29.2. Africa Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Anti-Cancer MAbS Market Competitive Landscape And Company Profiles

    30.1. Anti-Cancer MAbS Market Competitive Landscape

    30.2. Anti-Cancer MAbS Market Company Profiles

    30.2.1. Amgen Inc.

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Bristol Myers Squibb Company

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Eli Lilly and Company

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. F. Hoffmann-La Roche Ltd.

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. GlaxoSmithKline plc

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Global Anti-Cancer MAbS Market Competitive Benchmarking

    32. Global Anti-Cancer MAbS Market Competitive Dashboard

    33. Key Mergers And Acquisitions In The Anti-Cancer MAbS Market

    34. Anti-Cancer MAbS Market Future Outlook and Potential Analysis

    34.1 Anti-Cancer MAbS Market In 2028 - Countries Offering Most New Opportunities

    34.2 Anti-Cancer MAbS Market In 2028 - Segments Offering Most New Opportunities

    34.3 Anti-Cancer MAbS Market In 2028 - Growth Strategies

    34.3.1 Market Trend Based Strategies

    34.3.2 Competitor Strategies

    35. Appendix

    35.1. Abbreviations

    35.2. Currencies

    35.3. Historic And Forecast Inflation Rates

    35.4. Research Inquiries

    35.5. The Business Research Company

    35.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Anti-Cancer MAbS Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Anti-Cancer MAbS Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Amgen Inc. Financial Performance
  • Table 75: Bristol Myers Squibb Company Financial Performance
  • Table 76: Eli Lilly and Company Financial Performance
  • Table 77: F. Hoffmann-La Roche Ltd. Financial Performance
  • Table 78: GlaxoSmithKline plc Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Anti-Cancer MAbS Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Anti-Cancer MAbS Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Amgen Inc. Financial Performance
  • Figure 75: Bristol Myers Squibb Company Financial Performance
  • Figure 76: Eli Lilly and Company Financial Performance
  • Figure 77: F. Hoffmann-La Roche Ltd. Financial Performance
  • Figure 78: GlaxoSmithKline plc Financial Performance
Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company
Read More
Global Gene Therapy Market 2022 – Market Opportunities And Strategies
Read More
The Microbiome Market Share, Market Size, And Growth Rate 2022
Read More
Latest TNF Alpha Inhibitors Market Growth Study 2022-2026 By The Business Research Company
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the dermatitis market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the insulin drugs market research report 2022 with industry size, share, segments and market growth
Read More
Pain Management Devices And Therapies Global Market Report 2024 – By Type (Electrical Stimulators, Ablation Devices, Neurostimulators, Analgesic Pumps), By Neurostimulation Devices (Spinal Cord Stimulation (SCS) Devices, Deep Brain Stimulation Devices, Vagus Nerve Stimulation Devices, Sacral Nerve Stimulation Devices), By Electrical Stimulation Devices (Transcutaneous Electrical Nerve Stimulation (TENS) Devices, Neuromuscular Electrical Stimulation (NMES/EMS) Devices, Combination Devices, Electrotherapy Devices, TNS), By Ablation Devices (Radiofrequency Ablation Devices, Cryoablation Devices), By Analgesic Infusion Pumps (Intrathecal Infusion Pumps, External Infusion Pumps), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, Trauma) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Metabolomics Global Market Report 2024 – By Product & Service (Metabolomics Instruments, Metabolomics Bioinformatics Tools & Services), By Indication (Cancer, Cardiovascular Disorders, Neurological Disorders, Inborn Errors of Metabolism, Other Indications), By Application (Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics, Personalized Medicine, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Isothermal Nucleic Acid Amplification Technology (INAAT) Global Market Report 2024 – By Product (Instrument, Reagent), By Technology (NASBA, HAD), By Application (Blood Screening, Infectious Disease Diagnostics, Cancer), By End-User (Hospital, Reference Laboratories, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Monoclonal Antibodies (MAs) Global Market Report 2024 – By Source (Murine, Chimeric, Humanized, Human), By Application (Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAs), Neuropharmacological, Cardiovascular And Cerebrovascular, Other Applications), By End Users (Hospitals, Private Clinics, Research Institute) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Cancer biologics Global Market Report 2024 – By Type (Monoclonal Antibodies, Vaccines, Cell And Gene Therapy, Other Types), By Application (Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications), By Distribution Channel (Hospitals, Clinics, Other Distribution Channels) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Skin Cancer Drugs Global Market Report 2024 – By Type (Actinic Keratoses (AK), Basal cell carcinoma (BCC), Squamous cell carcinoma (SCC), Melanoma), By Drug Class (Chemotherapy, Immunotherapy, Targeted Agents & Other Drugs), By End Users (Hospitals, Cancer Research Centers, Clinics) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Pancreatic Cancer Drugs Global Market Report 2024 – By Type (Pancreatic Neuroendocrine Cancer Drugs, Pancreatic Exocrine Cancer Drugs), By Drug Combination (Single, Double, Triplet, Quadruplet), By End User (Hospital Pharmacies, Retail Pharmacies, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Lung Cancer Drugs Global Market Report 2024 – By Drugs (Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Other Drugs), By Disease Type (Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC)), By End User (Hospitals, Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report

Frequently Asked Questions

What is the definition of the anti-cancer MAbS market?

Anticancer monoclonal antibodies (mAbs) are the antibodies used for monoclonal antibody therapy to target and destroy cancer cells. These mAbs are intended to bind to specific proteins or chemicals located on the surface of cancer cells, preventing cancer growth, and spread. For further insights on the anti-cancer MAbS market, request a sample here

How will the anti-cancer MAbS market drivers and restraints affect the anti-cancer MAbS market dynamics? What forces will shape the anti-cancer MAbS industry going forward?

The anti-cancer MAbS market major growth driver - rising global cancer prevalence fuels anticancer monoclonal antibodies (mabs) market growth. For further insights on the anti-cancer MAbS market, request a sample here

What is the forecast market size or the forecast market value of the anti-cancer MAbS market ?

The anti-cancer MAbS market size has grown rapidly in recent years. It will grow from $59.98 billion in 2023 to $66.1 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to increasing cancer incidence rates, growing understanding of cancer biology, rise in personalized medicine approaches, increased investment in research and development, growing patient awareness and demand.. The anti-cancer MAbS market size is expected to see strong growth in the next few years. It will grow to $95.99 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to advancements in immunotherapy, increasing adoption of combination therapies, emergence of next-generation mabs, global efforts to address cancer burden, expansion of patient access programs.. Major trends in the forecast period include innovations in drug delivery technologies, integration of artificial intelligence in drug discovery, collaborations and partnerships in the pharma industry, advancements in biotechnology, car-t cell therapies.. For further insights on the anti-cancer MAbS market, request a sample here

How is the anti-cancer MAbS market segmented?

The anti-cancer MAbS market is segmented
1) By Type: Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, Other Types
2) By Application: Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, Other Applications
3) By End User: Hospitals, Research Institutes, Other End Users For further insights on the anti-cancer MAbS market, request a sample here

Which region has the largest share of the anti-cancer MAbS market? What are the other regions covered in the report?

North America was the largest region in the anti-cancer MAbS market in 2023. Asia Pacific is expected to be the fastest-growing region in the anti-cancer MAbS market during the forecast period. The regions covered in the anti-cancer MAbS market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the anti-cancer MAbS market, request a sample here.

Who are the major players in the anti-cancer MAbS market?

Major companies operating in the anti-cancer MAbS market report are Amgen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Merck & Co. Inc., Spectrum Pharmaceuticals Inc., AstraZeneca plc., Pfizer Inc., Gilead Sciences Inc., Bayer HealthCare, ImmunoGen Inc., Genentech Inc., AbbVie Inc., Takeda Pharmaceuticals, Seattle Genetics, Regeneron Pharmaceuticals, Celgene, Ipsen, Daiichi Sankyo, Kite Pharma, ADC Therapeutics, MacroGenics Inc., BioXcel Therapeutics, Zymeworks Inc., Exelixis Inc., Blueprint Medicines, Erytech Pharma, Oncopeptides AB . For further insights on the anti-cancer MAbS market, request a sample here.

What are the key trends in the anti-cancer MAbS market?

Major trend in the anti-cancer MAbS market - product innovations drive advancements in anticancer monoclonal antibodies (mabs) . For further insights on the anti-cancer MAbS market, request a sample here.

What are the major opportunities in the anti-cancer MAbS market? What are the strategies for the anti-cancer MAbS market?

For detailed insights on the major opportunities and strategies in the anti-cancer MAbS market, request a sample here.

How does the anti-cancer MAbS market relate to the overall economy and other similar markets?

For detailed insights on anti-cancer MAbS market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the anti-cancer MAbS industry?

For detailed insights on the mergers and acquisitions in the anti-cancer MAbS industry, request a sample here.

What are the key dynamics influencing the anti-cancer MAbS market growth? SWOT analysis of the anti-cancer MAbS market.

For detailed insights on the key dynamics influencing the anti-cancer MAbS market growth and SWOT analysis of the anti-cancer MAbS industry, request a sample here.